

Notice of Allowability

Application No.

10/695,024

Examiner

Ling-Siu Choi

Applicant(s)

BOWEN ET AL.

Art Unit

1713

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to the Amendment filed October 26, 2005.
2. ☒ The allowed claim(s) is/are 4-6, 8-19 and 21.
3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) ☐ All b) ☐ Some* c) ☐ None of the:
 1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

4. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
 5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
 - (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.
- Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☐ Notice of References Cited (PTO-892)
2. ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/08), Paper No./Mail Date _____
4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material
5. ☐ Notice of Informal Patent Application (PTO-152)
6. ☐ Interview Summary (PTO-413), Paper No./Mail Date _____
7. ☐ Examiner's Amendment/Comment
8. ☒ Examiner's Statement of Reasons for Allowance
9. ☐ Other _____

DETAILED ACTION

1. This Office Action is in response to the Amendment filed October 26, 2005. Claims 1-3, 7, and 20 were canceled. Claims 4-6, 8-19, and 21 are now pending.

Allowable Subject Matter

2. Claims 4-6, 8-19, and 21 are allowed.

3. The following is an examiner's statement of reasons for allowance:

The present claims are allowable over the closest references: Ender (US 3,287,291), Nakamura et al. (US 5,973,067), and Britton (US 5,618,951).

Ender discloses an organosilicon compound represented by the formula of $\text{Si}[(\text{OCH}_2)_n\text{OCH}_3]_4$ which includes $\text{Si}(\text{OCH}_2\text{OCH}_3)_4$, $\text{Si}[(\text{OCH}_2)_5\text{OC}_4\text{H}_9]_4$, $\text{Si}(\text{OCH}_2\text{OC}_2\text{H}_5)(\text{OCH}_2\text{OCH}_3)(\text{OCH}_2\text{OCH}_2\text{OC}_2\text{H}_5)(\text{OCH}_2\text{OCH}_2\text{OCH}_3)$, $\text{Si}(\text{OCH}_2\text{OCH}_3)[(\text{OCH}_2)_3\text{OCH}_3][(\text{OCH}_2)_2\text{OCH}_3][(\text{OCH}_2)_4\text{OCH}_3]$ (col. 1, lines 15-20; col. 2, lines 14-26). However, Ender does not teach or fairly suggest the claimed modified silane compound.

Nakamura et al. disclose a novel primer composition comprising an alkenyltrialkoxysilane, wherein the alkenyltrialkoxysilane can be allyltrimethoxysilane, allyltriethoxysilane, allyltri(ethoxymethoxy)silane, butenyltrimethoxysilane, hexenyltrimethoxysilane, or hexaenyltriethoxysilane (claims 1 and 3). However,

Art Unit: 1713


Nakamura et al. do not teach or fairly suggest the claimed modified silane compound.

Britton discloses 2,2-difluoroketene silyl acetal (claim 1, Formula I). However, Britton does not teach or fairly suggest the claimed modified silane compound.

Conclusion

4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ling-Siu Choi whose telephone number is 571-272-1098.

If attempt to reach the examiner by telephone are unsuccessful, the examiner's supervisor, David Wu, can be reach on 571-272-1114.


LING-SUI CHOI
PRIMARY EXAMINER

January 6, 2006